FEEDBACK PLC — Director's Dealing 2021

Dec 2, 2021

National Storage Mechanism | Additional information

RNS Number : 3698U

Feedback PLC

02 December 2021

Feedback plc

Director Dealings 

London, UK, 02 December 2021   - Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist clinical communication company, announces that further to the Fundraising, details of which were announced on 2 November 2021 and Admission which occurred on 30 November 2021, the following Directors' dealings as part of the Placing and Open Offer have completed:

Rory Shaw, Non Executive Chairman, has subscribed for 1,441,859 New Ordinary Shares through the Open Offer at the Issue Price of 0.7 pence per Ordinary Share.

Philipp Prince, Non Executive Director, has subscribed for 1,546,543 New Ordinary Shares through the Open Offer at the Issue Price of 0.7 pence per Ordinary Share.

Adam Denning, Non-Executive Director, has subscribed for 1,428,570 New Ordinary Shares through the Placing at the Issue Price of 0.7 pence per Ordinary Share.

Details of the Ordinary Shares held by these Directors are detailed in the table below:

Director/ PDMR	Position	Existing interest in Ordinary Shares	Ordinary Shares purchased	Total beneficial interest in Ordinary Shares	Total interest in Company's issued share capital
Rory Shaw	Non-Executive Chairman	9,818,780	1,441,859	11,260,639	0.4%
Philipp Prince	Non-Executive Director	2,500,000	1,546,543	4,046,543	0.2%
Adam Denning	Non-Executive Director	1,530,411	1,428,570	2,958,981	0.1%

The notification set out below, provides further details of such dealings:

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Names	Rory Shaw Philipp Prince Adam Denning
2	Reason for the notification
a)	Position/status	Non-Executive Chairman Non-Executive Director Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Feedback plc
b)	LEI	213800UGOF2GT2U2RV90
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of 0.25 pence each in Feedback plc
Identification code	GB0003340550
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)
		Price(s)	Volume(s)
		0.7p	1,441,859
		0.7p	1,546,543
		0.7p	1,428,570
d)	Aggregated information
- Aggregated volume	n/a
- Price
e)	Date of the transaction	30 November 2021
f)	Place of the transaction	XLON

The capitalised terms used in this announcement have the same meanings as in the announcement published by the Company at 7.01 a.m.  on 2 November 2021 unless otherwise stated.

Enquiries:

Feedback plc Tom Oakley, CEO Anesh Patel, CFO	+44 (0)1954 718072 IR@fbk.com
Panmure Gordon (UK) Limited (NOMAD and Broker) Emma Earl/Freddy Crossley (Corporate Finance) Rupert Dearden (Corporate Broking)	+44 (0)20 7886 2500
Walbrook PR Ltd	Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
Paul McManus/Nick Rome/Nicholas Johnson	07980 541 893 or 07748 325 236 or 07884 664 686

Notes to Editors

Feedback plc (AIM: FDBK) is a pioneer of regulated clinical communication products. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go. 

Its highly scalable Software as a Service ("SaaS") based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care providers. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of clinical review.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHUPGRGPUPGGUP